NextGxDx and athenahealth to Improve Clinicians' Genetic Testing Order Workflow

Published on:

NextGxDx Inc., the most comprehensive online marketplace for genetic testing, yesterday announced that through its work with athenahealth, Inc. (NASDAQ: ATHN), a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination, the companies will deliver an integrated platform to help clinicians more effectively navigate and improve genetic test ordering.

NextGxDx is designed to make the complex process of genetic testing simpler. Empowered by an intuitive user interface, physicians and other health care professionals can access up to date listings of all genetic tests from CLIA certified laboratories, order tests online, and receive results electronically. The company's bioinformatics team uses proprietary tools to update and curate test data.

By making the network of NextGxDx-affiliated labs visible within athenaClinicals, athenahealth's Best in KLAS EHR service, clinicians will have a streamlined genetic testing workflow, as well as a broader ordering network from which to order from.

Mark Harris, PhD, Chief Executive Officer, NextGxDx, who announced the new partnership from the stage of the Health 2.0 conference, said: "We believe in the vision of athenahealth, and both companies were founded on the premise that technology can help solve some of the inefficiencies in healthcare to deliver better results for patients and clinicians. We're honored to join forces with athenahealth to support their suite of solutions and provide their customers with an intuitive clinical interface for genetic testing."

"Genetic testing is becoming increasingly mainstream and more applicable to patient outcomes, but the rate of growth makes it difficult for clinicians to fully utilize these tests. athenahealth is dedicated to providing our customers with innovative healthcare solutions, and in collaborating with NextGxDx, we are thrilled to be the first to provide an integrated tool that will allow our clinicians to find and order the most clinically appropriate products," said Jasmine Gee, Director of Product Marketing, athenahealth.

For more information on NextGxDx, the most comprehensive database of genetic testing products in the U.S., visit its website,www.NextGxDx.com, or follow along on Twitter and Facebook.

For more information on athenahealth's full suite of cloud-based services for clinicians, please visit their website,www.athenahealth.com, or follow along on their blog, Twitter, and Facebook.

Related Content

Experts highlight 'significant concerns' with fluctuating accuracy of popular large language models
FDA clears AI screening tool for cardiac amyloidosis
Are providers too trusting of AI's advice?
Pairing an alert system with CAD software halves time-to-treatment for pneumothorax
Deep learning reconstruction cuts radiation and contrast dose by half in aortic CTA exams
New study highlights the need to include more challenging datasets in AI training

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.